Compare Schwab US Dividend Equity ETF (SCHD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs TG Therapeutics Inc — how do they compare? Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Schwab US Dividend Equity ETF is far larger — about 13.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Schwab US Dividend Equity ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 62 Days and TG Therapeutics Inc for 16 Days on average.
| SCHD | TGTX | |
|---|---|---|
Market Cap | $110.56B | $8.16B |
Volume | 23,539,168 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $59.06 |
52-Week Low | $26.44 | $26.94 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.15, up 1.53% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 by nearly 10 percentage points in 2026, with recent dividend growth attracting income-focused investors. Technical indicators show neutral oscillators but strong trend momentum with ADX readings above 60.
SCHD offers dividend growth potential with lower fees than competitors, though its defensive tilt may lag in growth markets. Key risks include interest rate sensitivity and methodology constraints that excluded high-performing stocks like Broadcom. The current pullback from August highs presents a potential entry point for long-term dividend investors.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
